Market Cap 54.83B
Revenue (ttm) 30.24B
Net Income (ttm) 712.32M
EPS (ttm) N/A
PE Ratio 10.73
Forward PE 10.87
Profit Margin 2.36%
Debt to Equity Ratio 0.65
Volume 4,396,900
Avg Vol 2,939,806
Day's Range N/A - N/A
Shares Out 3.18B
Stochastic %K 97%
Beta 0.03
Analysts Sell
Price Target $17.90

Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombi...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 81 3 3278-2111
Fax: 81 3 3278-2000
Address:
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan
EingeLTrade
EingeLTrade Feb. 2 at 4:39 PM
$TAK to $18+
0 · Reply
WallStW0lf
WallStW0lf Jan. 31 at 10:34 PM
$TAK Direction unresolved at present
0 · Reply
jlz1
jlz1 Jan. 29 at 8:57 PM
$TAK tell em about the dividend!
0 · Reply
WOLFSTREET
WOLFSTREET Jan. 29 at 4:36 PM
$TAK That was CC7, and alot has changed, I mean "a whole lot" in past 10 months as platform dev accelerated to CC9.5 today. TAK offerred a 4%+ Divi and good upside at the time so it got LISTED! It's looking pretty good right now against all oods. CC9.5 knows better, obviously.
0 · Reply
Estimize
Estimize Jan. 29 at 11:00 AM
$TAK reported - EPS and - revenue for Q3. http://www.estimize.com/intro/tak?chart=historical&metric_name=eps&utm_content=TAK&utm_medium=act
0 · Reply
Quantumup
Quantumup Jan. 28 at 4:38 PM
UBS⬆️ $ALKS's PT to $47 from $46/reit'd at a Buy rating. $AVDL $CNTA $TAK UBS said in its Note: ALKS stock is well-positioned to outperform in 2026, with 1) potential AVDL acquisition deal close in 1Q26, which brings in additional EBITDA growth and synergistic benefit to its Sleep franchise, and 2) two robust clinical catalysts: Lumryz and alixorexton IH trial read-outs. We believe ALKS FY26 guide for combined business could re-rate the stock: our pro-forma model (Figure 1 ALKS-AVDL Pro-forma assumptions) assumes certain level of OpEx synergies. We update our model on a pro-forma basis assuming AVDL acquisition, with a lower 4.5x EV/32E sales multiple (from ALKS prior 5.5x EV/'30E sales multiple) reflecting 1) our prior AVDL's 3.0x EV/'30E sales multiple and 2) most ALKS legacy commercial products losing exclusivity beyond 2032 with currently only a couple of early clinical-stage assets disclosed that have not been validated yet. This leads to our new PT of $47 (from $46), supported by DCF.
0 · Reply
EingeLTrade
EingeLTrade Jan. 27 at 3:47 PM
0 · Reply
Quantumup
Quantumup Jan. 27 at 2:00 PM
JPMorgan reiterated $VERA Overweight/$96 TVTX OTSKY $NVS JBIO $VRTX RHHBY IONS $AZN $TAK JPMorgan said in its note: We continue to see atacicept as well positioned in the IgAN B-Cell modulator space and still see significant upside in VERA shares (as competitive readouts occur, we see the potential for VERA shares to grind higher to a more appropriate probability-adjusted level, which is nearly double from current levels based on our model).
0 · Reply
Quantumup
Quantumup Jan. 27 at 12:39 PM
JPMorgan reiterated $PTGX Overweight; $93 and said, With shares pulling back from all-time highs in mid-Dec (-14% since Dec 12th), we wanted to re-evaluate the key levers in the story and discuss the set-up for the remainder of the year. $JNJ $ABVX $ALMS LLY ABBV PFE $TAK JPMorgan went on to say: https://x.com/Quantumup1/status/2016126900440043740?s=20
0 · Reply
EingeLTrade
EingeLTrade Jan. 26 at 2:43 PM
$TAK flying higher ✈️
0 · Reply
Latest News on TAK
US FDA investigates death tied to Takeda's blood disorder drug

Nov 21, 2025, 12:00 PM EST - 2 months ago

US FDA investigates death tied to Takeda's blood disorder drug


Takeda Pharmaceutical to exit cell therapy research

Oct 1, 2025, 9:41 AM EDT - 4 months ago

Takeda Pharmaceutical to exit cell therapy research


Shares of Asian drugmakers drop after Trump threatens tariffs

Sep 25, 2025, 10:52 PM EDT - 4 months ago

Shares of Asian drugmakers drop after Trump threatens tariffs


What's Going On With Takeda Stock On Friday?

Aug 22, 2025, 11:21 AM EDT - 5 months ago

What's Going On With Takeda Stock On Friday?


Takeda Announces New Assignments of Directors

Jun 25, 2025, 3:07 AM EDT - 7 months ago

Takeda Announces New Assignments of Directors


EingeLTrade
EingeLTrade Feb. 2 at 4:39 PM
$TAK to $18+
0 · Reply
WallStW0lf
WallStW0lf Jan. 31 at 10:34 PM
$TAK Direction unresolved at present
0 · Reply
jlz1
jlz1 Jan. 29 at 8:57 PM
$TAK tell em about the dividend!
0 · Reply
WOLFSTREET
WOLFSTREET Jan. 29 at 4:36 PM
$TAK That was CC7, and alot has changed, I mean "a whole lot" in past 10 months as platform dev accelerated to CC9.5 today. TAK offerred a 4%+ Divi and good upside at the time so it got LISTED! It's looking pretty good right now against all oods. CC9.5 knows better, obviously.
0 · Reply
Estimize
Estimize Jan. 29 at 11:00 AM
$TAK reported - EPS and - revenue for Q3. http://www.estimize.com/intro/tak?chart=historical&metric_name=eps&utm_content=TAK&utm_medium=act
0 · Reply
Quantumup
Quantumup Jan. 28 at 4:38 PM
UBS⬆️ $ALKS's PT to $47 from $46/reit'd at a Buy rating. $AVDL $CNTA $TAK UBS said in its Note: ALKS stock is well-positioned to outperform in 2026, with 1) potential AVDL acquisition deal close in 1Q26, which brings in additional EBITDA growth and synergistic benefit to its Sleep franchise, and 2) two robust clinical catalysts: Lumryz and alixorexton IH trial read-outs. We believe ALKS FY26 guide for combined business could re-rate the stock: our pro-forma model (Figure 1 ALKS-AVDL Pro-forma assumptions) assumes certain level of OpEx synergies. We update our model on a pro-forma basis assuming AVDL acquisition, with a lower 4.5x EV/32E sales multiple (from ALKS prior 5.5x EV/'30E sales multiple) reflecting 1) our prior AVDL's 3.0x EV/'30E sales multiple and 2) most ALKS legacy commercial products losing exclusivity beyond 2032 with currently only a couple of early clinical-stage assets disclosed that have not been validated yet. This leads to our new PT of $47 (from $46), supported by DCF.
0 · Reply
EingeLTrade
EingeLTrade Jan. 27 at 3:47 PM
0 · Reply
Quantumup
Quantumup Jan. 27 at 2:00 PM
JPMorgan reiterated $VERA Overweight/$96 TVTX OTSKY $NVS JBIO $VRTX RHHBY IONS $AZN $TAK JPMorgan said in its note: We continue to see atacicept as well positioned in the IgAN B-Cell modulator space and still see significant upside in VERA shares (as competitive readouts occur, we see the potential for VERA shares to grind higher to a more appropriate probability-adjusted level, which is nearly double from current levels based on our model).
0 · Reply
Quantumup
Quantumup Jan. 27 at 12:39 PM
JPMorgan reiterated $PTGX Overweight; $93 and said, With shares pulling back from all-time highs in mid-Dec (-14% since Dec 12th), we wanted to re-evaluate the key levers in the story and discuss the set-up for the remainder of the year. $JNJ $ABVX $ALMS LLY ABBV PFE $TAK JPMorgan went on to say: https://x.com/Quantumup1/status/2016126900440043740?s=20
0 · Reply
EingeLTrade
EingeLTrade Jan. 26 at 2:43 PM
$TAK flying higher ✈️
0 · Reply
Strategiso
Strategiso Jan. 25 at 9:36 PM
$ALT $OCUL Nice try to make a tie between $ALT and $SNY, but it's not happening. I confirmed with my BD contact (college buddy) that final framework for $OCUL is around $23/share but laughed when I mentioned $ALT. He said $SNY had an offer for full takeover of $ALT in March, 2025 for $3.1B (before 24W data) and Garg was arrogant, smug and impossible to work with so they walked. He said $ALT is blacklisted by $SNY now along with a few others (he only mentioned $TAK by name). Anyway, valiant effort, but no dice $ALT.
3 · Reply
BillionerOfKing
BillionerOfKing Jan. 23 at 1:25 AM
$TAK Current Stock Price: $15.94 Contracts to trade: $15 TAK Feb 20 2026 Call Entry: $0.85 Exit: $1.19 ROI: 40% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SparkyReturns
SparkyReturns Jan. 22 at 3:39 PM
$PFE Here's an idea for biotech investors. Big Pharma should pay attention to this tiny company that is saving lives and creating value. Look at the incredible setup for Seastar (ICU). 8M MC, with a TAM in the Billions (read that again); 2M NET revenue this year expected; 90% margins; Ramping up a product which will potentially/likely become Standard of Care for a number of conditions involving hyper-inflammation and sepsis (AKI, Cardiorenal, burn victims, transplant patients); Saves lives of AKI patients and ELIMINATES dialysis dependency; Total addressable market anywhere from 2B-20B; Zero debt; Pivotal adult AKI study to be completed in 12-15 months, possibly sooner; Being used at Mayo Clinic, Cinci Childrens, CHOP (Philadelphia), many more; 6 Breakthrough Device Designations (most ever); Cash burn reducing due to ramped up pediatric sales for longer runway; So, 8M MC for a company that will be worth Billions in a few years. $JNJ $TAK $NVS $MRK
0 · Reply
Quantumup
Quantumup Jan. 21 at 6:54 PM
Chardan🏁 $ALMS Buy/$37 $BMY $TAK ABBV $JNJ - $PTGX NVS LLY Here's what Chardan said in its initiation report: https://x.com/Quantumup1/status/2014048081944182966?s=20
0 · Reply
Quantumup
Quantumup Jan. 21 at 2:17 PM
Bernstein⬆️ $BEAM's PT to $41 from $37 and reiterated at an Outperform rating. $TAK - $ARWR $WVE - $GSK Bernstein said in its note: We increase our PT to $41 following last week's positive regulatory update on the AATD program. Briefly, the company announced it has aligned with FDA on an accelerated approval pathway for BEAM-302. There are always questions about how "real" the alignment is for these sorts of things, but we believe based on discussions with mgmt that this is about as real as it can get. We think there is still a sizable gap between the current share price and fair value—we think it's at least conceivable that pharma majors might be interested now that FDA has provided greater clarity on the AATD regulatory path.
0 · Reply
Quantumup
Quantumup Jan. 16 at 2:10 PM
Piper Sandler reiterated $CNTA Overweight-$38 and said, There are two main catalysts for CNTA shares this quarter. $ALKS $TAK $HRMY $ESALY Piper Sandler added, First, the company expects to start Phase 3 trials testing ORX750 in NT1, NT2, and IH. Second, CNTA expects to provide add'l data from the ongoing CRYSTAL-1 Phase 2 trial. We should receive data from at least one of the three indication cohorts. Of the three indications, we believe the most underappreciated question for investors is if orexin agonists can translate meaningfully into idiopathic hypersomnia (IH), a biologically heterogeneous indication that may ultimately represent a larger market opportunity than narcolepsy type 1 (NT1) or type 2 (NT2). Despite significant unmet need, IH remains a "black box" for the field. As such, even modest efficacy signals in IH could materially shift investor perception around the breadth of ORX750's opportunity and provides asymmetric risk-reward.
0 · Reply
Avocado_smash
Avocado_smash Jan. 15 at 1:43 PM
$TAK PT 17.09++
2 · Reply
Quantumup
Quantumup Jan. 15 at 1:27 PM
H.C. Wainwright reiterated $ORIC Buy/$23 $PFE $JNJ $TAK OTSKY $CGEM Here's what H.C. Wainwright said: https://x.com/Quantumup1/status/2011791470215286837?s=20
0 · Reply
Quantumup
Quantumup Jan. 14 at 9:19 PM
TD Cowen reiterated $CNTA at a Buy rating and said, As We Await Higher Dose Data For '750, Stock Pullback Is A Good Entry Point $ALKS $TAK $ESALY $HRMY TD Cowen went on to say: https://x.com/Quantumup1/status/2011547696134307872?s=20
0 · Reply
EingeLTrade
EingeLTrade Jan. 14 at 3:26 PM
👀 💊 Takeda Pharmaceutical Company $TAK
0 · Reply
jlz1
jlz1 Jan. 8 at 4:53 PM
$TAK 3.65% divi too!!!Lets goooo!! Should be a $20-30 + stock. Look at their strong financials!
0 · Reply
SantosSquire1021
SantosSquire1021 Jan. 6 at 5:18 PM
$CAH $MPC $CMG $TAK $ROP Nicely completed
0 · Reply